Ticiana Leal
Overview
Board certified in medical oncology and palliative care, Dr. Ticiana Leal specializes in caring for patients with lung cancer, mesothelioma and thymic malignancies at Winship Cancer Institute .
Dr. Leal holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.
Before joining Emory, Dr. Leal was a member of the faculty at UW Carbone Cancer Center in Madison, Wisconsin, where she served as team leader of the Thoracic Malignancies Disease Oriented Team.
Dr. Leal received her medical degree from Federal University of Ceara in Fortaleza, Brazil. She completed her residency in internal medicine at Weiss Memorial Hospital in Chicago, Illinois. She completed a fellowship in geriatric medicine atthe University of Illinois at Chicago, and a fellowship in medical oncology at theUniversity of Wisconsin Hospitals and Clinics in Madison, Wisconsin.
Dr. Leal's clinical research focuses on clinical trials of chemotherapy and/or immunotherapy agents to treat cancers of the lung. She has authored or coauthored numerous peer-reviewed original research articles, book chapters and posters. She serves as associate editor and as a member of the executive editorial board of The Journal of the National Comprehensive Cancer Network. She also serves as Lung Cancer Section Editor of Current Treatment Options in Oncology and on the editorial advisory boards of Cancer and The Brazilian Journal of Oncology.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Federal University of Ceara
Research
Publications
-
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
Cancer Volume: 131 Page(s): e35938
06/15/2025 Authors: Leal TA; Wang Y; Dowlati A; Chay CH; Chen Y; Mohindra AR; Razaq M; Ajuja HG; Liu J; King DM -
Clinical Outcomes of Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer.
JAMA Netw Open Volume: 8 Page(s): e2517953
06/02/2025 Authors: Desai A; Schwed K; Kalesinskas L; Yuan Q; Bryan J; Keane C; Fidyk E; Castellanos E; Cohen AB; Harrison K -
Maxing out with chemoimmunotherapy in extensive-stage small cell lung cancer.
Chin Clin Oncol Volume: 14 Page(s): 24
04/01/2025 Authors: Canaslan K; Xiao L; Leal T -
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
J Thorac Oncol Volume: 20 Page(s): 109 - 118
01/01/2025 Authors: Nassar AH; Jayakrishnan R; Feng J; Shepherd F; Adib E; Cheung JM; Lin JJ; Liu Y; Lin SH; Parikh K -
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
Future Oncol Volume: 21 Page(s): 63 - 71
01/01/2025 Authors: Higgins JP; Carlisle JW; Moniri NH; Gupta S; Oduah EI; Leal T -
Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
iScience Volume: 27 Page(s): 111133
11/15/2024 Authors: Sharma R; Sharma S; Shriwas P; Mehta L; Vu AH; Mouw JK; Koo J; Huang C; Matsuk VY; Tucker-Burden C -
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
J Exp Med Volume: 221
11/04/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y -
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States.
JCO Glob Oncol Volume: 10 Page(s): e2400138
09/01/2024 Authors: Liu SV; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Leal TA -
Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade.
J Clin Oncol Volume: 42 Page(s): 2367 - 2371
07/10/2024 Authors: Carlisle J; Liu Y; Leal T -
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol Volume: 19 Page(s): 928 - 940
06/01/2024 Authors: Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW